boschmain

Ace Inhibitor

Antihistamine

Antiplatelet

Antivival

Aminoglycosides

Beta Blocker

Calcium Antagonist

Cephalosporin

Coenzyme

Diaminopyvimidine

Loop Diuretic

Glucocorticoid

H2 Blocker

Haemostatic/
Fibronolytic

Lincosmide

Macrodile

Penicillin

Phenylacetic acid

Proton Pump Inhibitor

Statin

Quinolones

Untitled Document

Prelox offers Outstanding Benefits

* High effective against respiratory pathogens
*Achieve high tissue concentration.
*Excellent success rate in both URTI & LRTI.
* Ideal Sequential therapy from parenteral to oral
*Outstanding safety profile
* Converient dosage
*Suspension available in flavour.

*Economy with quality

Dosage

1 to 2 tablet b.i.d.

Presentation:
Prelox Tablets box of 1 x 10's in bilister

Prelox Susp.50ml(40mg/5 ml)

Invisibly Powerful,
Because...Has Excellent Coverage With Low MICs

S.pneumomiae H.influenzae M.Catarrhalis S.Pyogenes E.coil

Prelox 0.06 0.12 0.12 0.016 0.5

Cerftriaxone 0.1 0.05 0.12 0.05 0.2

Cefaclor 2.0 32 0.5 0.25 32

Amoxiclav 0.25 1.0 0.6 0.06 0.5

Cefuroxime 0.25 1.0 - 0.06 -

Prelox Highly Stable Against...

H.Inflienzae 35%

S.Pneumoniae 62%

M.Catarrhalis 80%

Prelox Achieves High Tissue & Fluid Concentration

Serum Bronchial Secretion Lung Parenchyma Bronchial Mucosa

1.7
(mg/L)
0.8
(mg/L) 0.89
(mg/kg) 0.91
(mg/kg)

Visibly Curative,
Because...Has High Success Rate In RTI's
The clinical and bacteriological result obtained with Cefpodoxime proxetil were comparable
with those obtained with Ceftriaxone in the treatment of community acquired pneumonia..

Clinical Response

Bacteriological Response

97.7% 93% 94.3% 97.7%

Cefpodoxime Ceftriaxone Cefpodoxime Ceftriaxone

Prelox Has Excellent Safety Profile

2.5%

11.0%

27.0%

Prelox

CXefaclor

Amoxiclav

Prelox (cefpodoxime) is well tolerated with only 2.29% undesirable effects.

Prelox Has excellent Coverage of pathogens involved in Urinary infections

E.coli P.mirabilis Klebsiella

Prelox 0.5 0.25 0.25

Cafaclor 8.0 <128 8.0

Amoxiclav 8.0 4 2.0

Visibly Curative,
Because
Prelox exhibit high clinical efficacy in Urinary Tract infections

98%

92%

Urethritis

Cystitis